[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-212860-en":3,"doc-seo-212860-105":30,"detail-sidebar-cat-0-en-105":91},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"site_id":24,"html_lang":23,"table_of_contents":25,"faqs":26,"seo_title":27,"seo_description":14,"update_tm":28,"read_time":29},212860,3573418547284,"Graffin","https://eur-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d",7,"Healthcare","Provesica Starts Phase 2 Study in Overactive Bladder","Provesica Ltd announced the initiation of a Phase 2 clinical study for overactive bladder using its lead investigational drug XEN-D0501. The therapy targets the TRPV1 receptor, aiming to validate a mechanism that is established yet not fully exploited for OAB. The study will enroll 180 evaluable subjects across 26 UK, Belgium, Russia, Estonia, and Romania sites, evaluating symptoms including frequency, urgency, and incontinence. Provesica positions this effort as a potential first-in-class clinical proof of concept.","For release: 1 March 2011  \nProvesica Starts Phase 2 Study in Overactive Bladder  \nCAMBRIDGE, UK – PROVESICA LTD, a clinical-stage company developing a novel therapeutic approach to overactive bladder, announced today that it had initiated a Phase 2 study of overactive bladder with its lead product XEN-D0501 .  \nXEN-D0501 is an antagonist of the TRPV1 receptor which is expressed both in the bladder and on the afferent nerve pathway. The compound has shown promising efficacy in pre-clinical models of overactive bladder and recently completed Phase 1 clinical trials and was shown to be safe and well tolerated.  \nThe Phase 2 study will aim to recruit 180 evaluable subjects suffering from overactive bladder at 26 clinical sites in the United Kingdom, Belgium, Russia, Estonia and Romania. The study will assess the symptoms of OAB such as frequency, urgency and incontinence. The first patients have now been enrolled into the study.  \nCommenting on the news Tim Brears, Managing Director of Provesica, said: ‘Starting this study isan important step forward for Provesica. XEN-D0501 targets TRPV1, a well-established but not yet exploited mechanism for overactive bladder, and, if successful, we will be the first to demonstrate clinical proof of concept for this mechanism. We are therefore very excited to be playing a leading role in the development of novel overactive bladder therapeutics with a potential first-in-class drug’.  \nOveractive bladder represents an area of huge unmet medical need affecting over 60 million people in the major seven pharmaceutical economies. It has a substantial impact on quality of life, but despite its significance, current therapeutic approaches have a poor side-effect profile and are generally not very effective.  \nFor further information, please contact:  \nTim Brears 01223 493 900  \nManaging Director Provesica Limited  \nProvesica Limited, Iconix Park London Road, Pampisford Cambridge CB22 3EG  \nTel: +44 (0)1223 493900  \nFax: +44 (0)1223 493901 [www.provesica.com](www.provesica.com)  \nAnna Dunphy / Mike Wort 020 7861 3838  \nDe Facto Communications  \nAbout Overactive Bladder:  \nOveractive bladder (OAB) is a condition that affects over 60 million people in the major seven pharmaceutical economies. It has a huge impact on quality of life. Despite its significance, therapeutic approaches, which mainly rely on the blockade of muscarinic receptors, have a poor side-effect profile and are generally not very effective. There is a clear need for novel therapeutic agents to treat OAB.  \nNotes to Editors:  \nProvesica Ltd is a clinical-stage company developing a novel therapeutic approach to overactive bladder, an area of significant unmet medical need. Provesica’s development compound, XEND0501, targets TRPV1, a well-established but not yet exploited mechanism for overactive bladder. Provesica was established in November 2010 as part of the reorganisation of Xention and raised £4 million from Forbion Capital Partners and Seroba Kernel Life Sciences Ltd. Provesica collaborates with Xention in the area of clinical development. For further information, please see [http://www.provesica.com](http://www.provesica.com).","cbCaiitSwq9S6nrn","https://ap.wps.com/l/cbCaiitSwq9S6nrn","pdf",49680,1,2,"English","en",105,"# Provesica initiates Phase 2 study\n## Target and rationale for XEN-D0501\n## Study design, sites, and enrollment\n## Expected assessment of OAB symptoms\n## Background on unmet medical need and TRPV1 mechanism","[{\"question\":\"What Phase 2 study did Provesica start?\",\"answer\":\"Provesica started a Phase 2 study in overactive bladder to recruit evaluable subjects for clinical assessment of symptoms.\"},{\"question\":\"What is XEN-D0501 and what does it target?\",\"answer\":\"XEN-D0501 is an antagonist of the TRPV1 receptor, expressed in the bladder and on the afferent nerve pathway.\"},{\"question\":\"How many subjects and where will the Phase 2 study be conducted?\",\"answer\":\"The study aims to recruit 180 evaluable subjects at 26 clinical sites in the UK, Belgium, Russia, Estonia, and Romania.\"}]","Provesica Starts Phase 2 Study in Overactive Bladder | PDF",1788749606,5,{"code":4,"msg":31,"data":32},"ok",{"site_id":24,"language":23,"slug":33,"title":13,"keywords":34,"description":14,"schema_data":35,"social_meta":86,"head_meta":88,"extra_data":90,"updated_unix":28},"provesica-starts-phase-2-study-in-overactive-bladder","",{"@graph":36,"@context":85},[37,53,68],{"@type":38,"itemListElement":39},"BreadcrumbList",[40,44,47,50],{"item":41,"name":42,"@type":43,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":45,"name":46,"@type":43,"position":21},"https://docshare.wps.com/document/","Document",{"item":48,"name":12,"@type":43,"position":49},"https://docshare.wps.com/document/healthcare/",3,{"item":51,"name":13,"@type":43,"position":52},"https://docshare.wps.com/document/provesica-starts-phase-2-study-in-overactive-bladder/212860/",4,{"url":51,"name":13,"@type":54,"author":55,"headline":13,"publisher":57,"fileFormat":60,"inLanguage":23,"description":14,"dateModified":61,"datePublished":62,"encodingFormat":60,"isAccessibleForFree":63,"interactionStatistic":64},"DigitalDocument",{"name":9,"@type":56},"Person",{"url":41,"name":58,"@type":59},"DocShare","Organization","application/pdf","2026-09-11","2026-09-07",true,{"@type":65,"interactionType":66,"userInteractionCount":20},"InteractionCounter",{"@type":67},"ViewAction",{"@type":69,"mainEntity":70},"FAQPage",[71,77,81],{"name":72,"@type":73,"acceptedAnswer":74},"What Phase 2 study did Provesica start?","Question",{"text":75,"@type":76},"Provesica started a Phase 2 study in overactive bladder to recruit evaluable subjects for clinical assessment of symptoms.","Answer",{"name":78,"@type":73,"acceptedAnswer":79},"What is XEN-D0501 and what does it target?",{"text":80,"@type":76},"XEN-D0501 is an antagonist of the TRPV1 receptor, expressed in the bladder and on the afferent nerve pathway.",{"name":82,"@type":73,"acceptedAnswer":83},"How many subjects and where will the Phase 2 study be conducted?",{"text":84,"@type":76},"The study aims to recruit 180 evaluable subjects at 26 clinical sites in the UK, Belgium, Russia, Estonia, and Romania.","https://schema.org",{"og:url":51,"og:type":87,"og:title":13,"og:site_name":58,"og:description":14},"article",{"robots":89,"canonical":51},"index,follow",{"doc_id":7,"site_id":24},{"code":4,"msg":5,"data":92},[93,97,101,105,109,114,117,122,127,130,134],{"id":20,"doc_module":4,"doc_module_name":46,"category_name":94,"show_sort_weight":95,"slug":96},"Story & Novel",90,"story-novel",{"id":21,"doc_module":4,"doc_module_name":46,"category_name":98,"show_sort_weight":99,"slug":100},"Literature",80,"literature",{"id":52,"doc_module":4,"doc_module_name":46,"category_name":102,"show_sort_weight":103,"slug":104},"Exam",70,"exam",{"id":29,"doc_module":4,"doc_module_name":46,"category_name":106,"show_sort_weight":107,"slug":108},"Comic",60,"comic",{"id":110,"doc_module":4,"doc_module_name":46,"category_name":111,"show_sort_weight":112,"slug":113},6,"Technology",50,"technology",{"id":11,"doc_module":4,"doc_module_name":46,"category_name":12,"show_sort_weight":115,"slug":116},40,"healthcare",{"id":118,"doc_module":4,"doc_module_name":46,"category_name":119,"show_sort_weight":120,"slug":121},8,"Research & Report",30,"research-report",{"id":123,"doc_module":4,"doc_module_name":46,"category_name":124,"show_sort_weight":125,"slug":126},9,"Religion & Spirituality",20,"religion-spirituality",{"id":125,"doc_module":4,"doc_module_name":46,"category_name":128,"show_sort_weight":125,"slug":129},"World Cup","world-cup",{"id":131,"doc_module":4,"doc_module_name":46,"category_name":132,"show_sort_weight":131,"slug":133},10,"Lifestyle","lifestyle",{"id":135,"doc_module":4,"doc_module_name":46,"category_name":136,"show_sort_weight":29,"slug":137},19,"General","general"]